Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9795269, 10 pages
http://dx.doi.org/10.1155/2016/9795269
Review Article

Clinically Meaningful Use of Blood Tumor Markers in Oncology

1University of Bonn, Bonn, Germany
2Mayo Clinic, Department of Oncology, Division of Medical Oncology, Rochester, MN, USA
3Roche Diagnostics, Indianapolis, USA
4Roche Diagnostics International, Rotkreuz, Switzerland

Received 20 April 2016; Accepted 17 October 2016

Academic Editor: Franco M. Buonaguro

Copyright © 2016 Stefan Holdenrieder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Steinberg, “The clinical utility of the CA 19-9 tumor-associated antigen,” The American Journal of Gastroenterology, vol. 85, no. 4, pp. 350–355, 1990. View at Google Scholar · View at Scopus
  2. M. Hara, Y. Kanemitsu, T. Hirai, K. Komori, and T. Kato, “Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study,” Diseases of the Colon and Rectum, vol. 51, no. 11, pp. 1675–1680, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule (CLAB), 2016, https://www.cms.gov/Medicare/Medicare-fee-for-service-Payment/clinicallabfeesched/index.html.
  4. M. J. Duffy, J. M. Bonfrer, J. Kulpa et al., “CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 679–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Ducreux, A. S. Cuhna, C. Caramella et al., “Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 26, supplement 5, pp. v56–v68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Bruix, M. Sherman, and American Association for the Study of Liver Diseases, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Verslype, O. Rosmorduc, and P. Rougier, “Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii41–vii48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Cardoso, A. Costa, L. Norton et al., “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2),” Annals of Oncology, vol. 25, no. 10, pp. 1871–1888, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Cardoso, A. Costa, L. Norton et al., “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2),” Breast, vol. 23, no. 5, pp. 489–502, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Y. Locker, S. Hamilton, J. Harris et al., “ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5313–5327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Meyerhardt, P. B. Mangu, P. J. Flynn et al., “Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement,” Journal of Clinical Oncology, vol. 31, no. 35, pp. 4465–4470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Carroll and A. J. Vickers, “Point/counterpoint: Early detection of prostate cancer: do the benefits outweigh the consequences?” Journal of the National Comprehensive Cancer Network, vol. 12, no. 5, pp. 768–771, 2014. View at Google Scholar · View at Scopus
  13. C. M. Korse, S. Holdenrieder, X.-Y. Zhi et al., “Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China,” Clinica Chimica Acta, vol. 438, pp. 388–395, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Huhtinen, P. Suvitie, J. Hiissa et al., “Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts,” British Journal of Cancer, vol. 100, no. 8, pp. 1315–1319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. T. Ichiki, S. Krauss, K. L. Israelsen, T. Sonoda, and I. R. Collmann, “Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer,” Oncology, vol. 38, no. 1, pp. 27–30, 1980. View at Google Scholar · View at Scopus
  16. A. van der Gaast, C. H. H. Schoenmakers, T. C. Kok, B. G. Blijenberg, F. Cornillie, and T. A. W. Splinter, “Evaluation of a new tumour marker in patients with non-small-cell lung cancer: cyfra 21.1,” British Journal of Cancer, vol. 69, no. 3, pp. 525–528, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Schwaederle, M. Zhao, J. J. Lee et al., “Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials,” Journal of Clinical Oncology, vol. 33, no. 32, pp. 3817–3825, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. E. Hardingham, P. Grover, M. Winter, P. J. Hewett, T. J. Price, and B. Thierry, “Detection and clinical significance of circulating tumor cells in colorectal cancer—20 years of progress,” Molecular Medicine, vol. 21, supplement 1, pp. S25–S31, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. D. F. Hayes and A. F. Schott, “Personalized medicine: genomics trials in oncology,” Transactions of the American Clinical and Climatological Association, vol. 126, pp. 133–143, 2015. View at Google Scholar
  20. B. T. Li, A. Drilon, M. L. Johnson et al., “A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers,” Annals of Oncology, vol. 27, no. 1, pp. 154–159, 2015. View at Publisher · View at Google Scholar
  21. C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Science Translational Medicine, vol. 6, no. 224, p. 224ra24, 2014. View at Publisher · View at Google Scholar
  22. I. Garcia-Murillas, G. Schiavon, B. Weigelt et al., “Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer,” Science Translational Medicine, vol. 7, no. 302, Article ID 302ra133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Kato, J. Uchida, Y. Kukita et al., “Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients,” Scientific Reports, vol. 6, Article ID 29093, 2016. View at Publisher · View at Google Scholar
  24. J. J. Chabon, A. D. Simmons, A. F. Lovejoy et al., “Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients,” Nature Communications, vol. 7, article 11815, 2016. View at Publisher · View at Google Scholar
  25. J. Tie, Y. Wang, C. Tomasetti et al., “Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer,” Science Translational Medicine, vol. 8, no. 346, Article ID 346ra92, 2016. View at Publisher · View at Google Scholar
  26. P. Sidaway, “Urological cancer: genetics of mCRPC tracked in ctDNA,” Nature Reviews Clinical Oncology, vol. 13, no. 7, p. 398, 2016. View at Publisher · View at Google Scholar
  27. S. Chang-Hao Tsao, J. Weiss, C. Hudson et al., “Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations,” Scientific Reports, vol. 5, article 11198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Joyner and N. Paneth, “Seven questions for personalized medicine,” The Journal of the American Medical Association, vol. 314, no. 10, pp. 999–1000, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Ledermann, F. A. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo, and C. Sessa, “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 24, supplement 6, pp. vi24–vi32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Lokich, M. Palisoul, N. Romano et al., “Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass,” Gynecologic Oncology, vol. 139, no. 2, pp. 248–252, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. D. R. Aberle, A. M. Adams, C. D. Berg et al., “Reduced lung-cancer mortality with low-dose computed tomographic screening,” New England Journal of Medicine, vol. 365, no. 5, pp. 395–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. R. S. Wiener, D. R. Ouellette, E. Diamond et al., “An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine,” Chest, vol. 145, no. 6, pp. 1383–1391, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Molina, R. M. Marrades, J. M. Augé et al., “Assessment of a combined panel of six serum tumor markers for lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 4, pp. 427–437, 2016. View at Publisher · View at Google Scholar
  34. M. M. Wahidi, J. A. Govert, R. K. Goudar, M. K. Gould, D. C. McCrory, and American College of Chest Physicians, “Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition),” Chest, vol. 132, supplement 3, pp. 94S–107S, 2007. View at Publisher · View at Google Scholar
  35. U.-H. Stenman, J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen, and O. Alfthan, “A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer,” Cancer Research, vol. 51, no. 1, pp. 222–226, 1991. View at Google Scholar · View at Scopus
  36. W. J. Catalona, A. W. Partin, K. M. Slawin et al., “Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial,” The Journal of the American Medical Association, vol. 279, no. 19, pp. 1542–1547, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Grönberg, J. Adolfsson, M. Aly et al., “Prostate cancer screening in men aged 50–69 years (STHLM3): A Prospective Population-based Diagnostic Study,” The Lancet Oncology, vol. 16, no. 16, pp. 1667–1676, 2015. View at Publisher · View at Google Scholar
  38. National Comprehensive Cancer Network (NCCN), Occult Primary (Cancer of Unknown Primary [CUP]); Version 1.2015, 2015, http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf.
  39. T. Muley, Y. He, V. Rolny et al., “The combination of serum biomarkers CYFRA 21-1 and CEA in the prognostication of early stage non-small cell lung cancer (NSCLC),” Journal of Thoracic Oncology, vol. 10, no. 9, supplement 2, p. S382, 2015. View at Google Scholar
  40. T. Muley, X. Zhang, S. Holdenrieder et al., “Progastrin-releasing peptide (ProGRP) as a biomarker for clinical response in small-cell lung carcinoma (SCLC),” Journal of Thoracic Oncology, vol. 10, no. 9, supplement 2, p. S363, 2015. View at Google Scholar
  41. D. Di Gioia, M. Dresse, D. Mayr, D. Nagel, V. Heinemann, and P. Stieber, “Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer,” Clinica Chimica Acta, vol. 440, pp. 16–22, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. N. Fahmueller, D. Nagel, R.-T. Hoffmann et al., “CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing selective internal radiation therapy,” International Journal of Clinical Pharmacology and Therapeutics, vol. 51, no. 1, pp. 63–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. F. G. Ebeling, P. Stieber, M. Untch et al., “Serum CEA and CA 15-3 as prognostic factors in primary breast cancer,” British Journal of Cancer, vol. 86, no. 8, pp. 1217–1222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. F. C. Ebeling, U. M. Schmitt, M. Untch et al., “Tumour markers CEA and CA 15-3 as prognostic factors in breast cancer—univariate and multivariate analysis,” Anticancer Research, vol. 19, no. 4, pp. 2545–2550, 1999. View at Google Scholar · View at Scopus
  45. D. D. Von Hoff, T. Ervin, F. P. Arena et al., “Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine,” New England Journal of Medicine, vol. 369, no. 18, pp. 1691–1703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Conroy, F. Desseigne, M. Ychou et al., “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer,” The New England Journal of Medicine, vol. 364, no. 19, pp. 1817–1825, 1817. View at Google Scholar
  47. A. V. D'Amico, R. Whittington, S. B. Malkowicz et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” The Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. E. A. Klein, “Tumor markers in testis cancer,” Urologic Clinics of North America, vol. 20, no. 1, pp. 67–73, 1993. View at Google Scholar · View at Scopus
  49. C. M. Sturgeon, M. J. Duffy, U.-H. Stenman et al., “National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers,” Clinical Chemistry, vol. 54, no. 12, pp. e11–e79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. National Academy of Clinical Biochemistry, Use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers, 2009, https://www.aacc.org/science-and-practice/practice-guidelines/major-tumor-markers.
  51. M. K. Accordino, J. D. Wright, S. Vasan et al., “Serum tumor marker use in patients with advanced solid tumors,” Journal of Oncology Practice, vol. 12, no. 1, pp. 65–66, 2016. View at Publisher · View at Google Scholar
  52. B. Nakata, Y. S. C. K. Hirakawa, Y. Kato et al., “Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma,” Cancer, vol. 83, no. 12, pp. 2488–2492, 1998. View at Publisher · View at Google Scholar
  53. J. S. Frenel, S. Carreira, J. Goodall et al., “Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration,” Clinical Cancer Research, vol. 21, no. 20, pp. 4586–4596, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S.-J. Dawson, D. W. Y. Tsui, M. Murtaza et al., “Analysis of circulating tumor DNA to monitor metastatic breast cancer,” New England Journal of Medicine, vol. 368, no. 13, pp. 1199–1209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Tjensvoll, M. Lapin, T. Buhl et al., “Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer,” Molecular Oncology, vol. 10, no. 4, pp. 635–643, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. V. Stearns, H. Yamauchi, and D. F. Hayes, “Circulating tumor markers in breast cancer: accepted utilities and novel prospects,” Breast Cancer Research and Treatment, vol. 52, no. 1–3, pp. 239–259, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Müller, N. Stahmann, S. Riethdorf et al., “Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity,” Clinical Cancer Research, vol. 11, no. 10, pp. 3678–3685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Lupini, C. Bassi, J. Mlcochova et al., “Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients,” BMC Cancer, vol. 15, no. 1, article no. 808, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Katakami, S. Atagi, K. Goto et al., “LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both,” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3335–3341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. F. Petrelli, K. Borgonovo, M. Cabiddu, and S. Barni, “Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: a meta-analysis of 13 randomized trials,” Clinical Lung Cancer, vol. 13, no. 2, pp. 107–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. J. O'Shaughnessy, D. R. Feldman, B. S. Carver, and J. Sheinfeld, “Late relapse of testicular germ cell tumors,” Urologic Clinics of North America, vol. 42, no. 3, pp. 359–368, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. National Comprehensive Cancer Network (NCCN), Testicular cancer; Version 1.2016. 2015, http://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
  63. R. Labianca, B. Nordlinger, G. D. Beretta et al., “Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 24, supplement 6, Article ID mdt354, pp. vi64–vi72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Parker, S. Gillessen, A. Heidenreich, and A. Horwich, “Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 26, supplement 5, Article ID mdv222, pp. v69–v77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Vizcarra, A. Lluch, R. Cibrian, F. Jarque, and J. Garcia-Conde, “CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse,” Oncology, vol. 51, no. 6, pp. 491–496, 1994. View at Google Scholar · View at Scopus
  66. A. C. Pedersen, P. D. Sørensen, E. H. Jacobsen, J. S. Madsen, and I. Brandslund, “Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 7, pp. 1511–1519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Stieber, R. Molina, D. W. Chan et al., “Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients,” Clinical Laboratory, vol. 49, no. 1-2, pp. 15–24, 2003. View at Google Scholar · View at Scopus
  68. P. Stieber and V. Heinemann, “Sinnvoller einsatz von tumormarkern,” The Journal of Laboratory Medicine, vol. 32, pp. 339–360, 2008. View at Google Scholar
  69. D. L. Clarke-Pearson, “Screening for ovarian cancer,” The New England Journal of Medicine, vol. 361, no. 2, pp. 170–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. G. J. S. Rustin, M. E. L. van der Burg, C. L. Griffin et al., “Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial,” The Lancet, vol. 376, no. 9747, pp. 1155–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. R. C. Bast Jr., “CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease,” Cancer, vol. 116, no. 12, pp. 2850–2853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. R. T. Morris and B. J. Monk, “Ovarian cancer: relevant therapy, not timing, is paramount,” The Lancet, vol. 376, no. 9747, pp. 1120–1122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. J. N. Primrose, R. Perera, A. Gray et al., “Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial,” The Journal of the American Medical Association, vol. 311, no. 3, pp. 263–270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Niklinski and M. Furman, “Clinical tumour markers in lung cancer,” European Journal of Cancer Prevention, vol. 4, no. 2, pp. 129–138, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. R.-F. Wang, B.-R. Song, J.-J. Peng et al., “The prognostic value of preoperative serum CEA and CA19-9 values in stage I-III colorectal cancer,” Hepato-Gastroenterology, vol. 61, no. 132, pp. 994–999, 2014. View at Google Scholar · View at Scopus
  76. I. Heliström, J. Raycraft, M. Hayden-Ledbetter et al., “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3695–3700, 2003. View at Google Scholar · View at Scopus
  77. U. Menon, A. Ryan, J. Kalsi et al., “Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening,” Journal of Clinical Oncology, vol. 33, no. 18, pp. 2062–2071, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. A. J. Vickers and S. F. Brewster, “PSA velocity and doubling time in diagnosis and prognosis of prostate cancer,” British Journal of Medical and Surgical Urology, vol. 5, no. 4, pp. 162–168, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. K. P. Wevers, S. Kruijff, M. J. Speijers, E. Bastiaannet, A. C. Muller Kobold, and H. J. Hoekstra, “S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma,” Annals of Surgical Oncology, vol. 20, no. 8, pp. 2772–2779, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. S. K. Huang and D. S. B. Hoon, “Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients,” Molecular Oncology, vol. 10, no. 3, pp. 450–463, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Charpin, A. K. Bhan, V. R. Zurawski Jr., and R. E. Scully, “Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies,” International Journal of Gynecological Pathology, vol. 1, no. 3, pp. 231–245, 1982. View at Publisher · View at Google Scholar · View at Scopus
  82. R. C. Bast Jr., T. L. Klug, E. St John et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,” The New England Journal of Medicine, vol. 309, no. 15, pp. 883–887, 1983. View at Publisher · View at Google Scholar · View at Scopus
  83. L. R. Purves, M. Macnab, and I. Bersohn, “Serum alpha-feto-protein. I. Immunodiffusion and immuno-assay results in cases of primary cancer of the liver,” South African Medical Journal, vol. 42, no. 42, pp. 1138–1141, 1968. View at Google Scholar · View at Scopus
  84. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus